{
  "slug": "blueprint-medicines",
  "name": "Blueprint Medicines",
  "description": "Blueprint Medicines is a biopharmaceutical company focused on pioneering science to develop targeted therapies that transform the lives of patients with genetically defined diseases, particularly in areas of cancer and rare allergic/inflammatory diseases like systemic mastocytosis and gastrointestinal stromal tumors (GIST). They emphasize urgency, scientific rigor, and patient impact.",
  "url": "https://optimly.ai/brand/blueprint-medicines",
  "websiteUrl": null,
  "logoUrl": "https://logo.clearbit.com/https://www.blueprintmedicines.com/",
  "baiScore": 50,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Incumbent",
  "archetype_status": "active",
  "category": "Biotechnology",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-07-26T00:03:00.901Z",
  "verifiedVitals": {
    "website": "https://www.blueprintmedicines.com/",
    "founded": "Not specified in context.",
    "headquarters": "Not specified in context",
    "pricing_model": "Not disclosed; typical for specialized pharmaceutical products.",
    "core_products": "Avapritinib (AYVAKIT®), Elenestinib, BLU-808",
    "key_differentiator": "Pioneering science to target the root causes of genetically defined diseases, a proven track record of developing approved medicines, and an urgent, patient-centric approach to accelerate therapy development.",
    "target_markets": "Adults with indolent and advanced systemic mastocytosis, adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring PDGFRA exon 18 mutations, and patients with chronic spontaneous and inducible urticaria and other mast cell-mediated diseases, as well as broader allergic/inflammatory and cancer populations.",
    "employee_count": "Not specified in context, but implied to be substantial given the 'diverse team' and global operations mentioned by a Senior Director.",
    "funding_stage": "Publicly traded, as indicated by investor relations and earnings call mentions, and acquired by Sanofi.",
    "subcategory": "Targeted Oncology and Rare Disease Therapeutics"
  },
  "intentTags": {
    "problemIntents": [
      "Traditional Small Molecule Drug Discovery: Relying on conventional, labor-intensive biochemical screens and medicinal chemistry without leveraging advanced computational modeling or AI-driven target i",
      "Contract Research Organizations (CROs): Outsourcing significant portions of clinical trial design, management, data collection, and analysis to specialized third-party CROs instead of building extensi",
      "Status Quo R&D: Continuing with existing drug development methodologies without adopting newer technologies or strategic approaches to accelerate research, potentially leading to slower discovery time"
    ],
    "solutionIntents": [
      "Blueprint Medicines treatments",
      "AYVAKIT indications",
      "Careers Blueprint Medicines",
      "Advanced Bioinformatics Platforms: Utilizing sophisticated bioinformatics and genomics software suites for data analysis and target validation, but without the integrated predictive power or autonomou"
    ],
    "evaluationIntents": []
  },
  "timestamp": 1785232592895
}